Shanxi Zhendong Pharmaceutical Co.,Ltd (SHE:300158)
China · Delayed Price · Currency is CNY 5.72
-0.04 (-0.69%)
Feb 4, 2026, 12:14 PM CST
SHE:300158 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Net Income | -1,348 | -1,329 | -43.98 | -51.29 | 2,617 | 262.03 |
Depreciation & Amortization | 108.9 | 108.9 | 121.68 | 126.01 | 125.13 | 166.29 |
Other Amortization | 11.16 | 11.16 | 8.81 | 21.04 | 23.04 | 34.85 |
Loss (Gain) From Sale of Assets | -11.26 | -11.26 | 0.29 | 0.54 | -0 | 10.65 |
Asset Writedown & Restructuring Costs | 44.22 | 44.22 | 7.62 | 0.94 | 13.64 | 0.02 |
Loss (Gain) From Sale of Investments | 97.47 | 97.47 | -45.04 | -66.05 | -2,954 | -13.98 |
Provision & Write-off of Bad Debts | -5.32 | -5.32 | -20.16 | -14.04 | -6.83 | 29.74 |
Other Operating Activities | -220 | 252.21 | 28.66 | -19.73 | 33.74 | 7.05 |
Change in Accounts Receivable | 115 | 115 | 97.98 | 319.57 | 303.08 | -202.15 |
Change in Inventory | 176.5 | 176.5 | -132.44 | -141.24 | -163.18 | -255.4 |
Change in Accounts Payable | 270.36 | 270.36 | -266.99 | -78.98 | 320.12 | 163.6 |
Change in Income Taxes | - | - | - | -4.98 | - | - |
Change in Other Net Operating Assets | 122.77 | 122.77 | -3.75 | -15.42 | -39 | 22.36 |
Operating Cash Flow | -641.79 | -149.82 | -249.17 | 81.32 | 284.45 | 221.94 |
Operating Cash Flow Growth | - | - | - | -71.41% | 28.16% | 19.10% |
Capital Expenditures | -185.92 | -298.48 | -116.21 | -145.81 | -151.66 | -183.96 |
Sale of Property, Plant & Equipment | -0.04 | 7.77 | - | 1.09 | - | 13.66 |
Divestitures | -0.04 | 0.99 | - | - | 4,961 | - |
Investment in Securities | 769.07 | 282.26 | 529.83 | 2,464 | -4,462 | 199.55 |
Other Investing Activities | 21.75 | 46.97 | 59.22 | 77.77 | 2.24 | 14.91 |
Investing Cash Flow | 604.81 | 39.51 | 472.84 | 2,397 | 348.85 | 44.16 |
Short-Term Debt Issued | - | 38.11 | 0.1 | - | - | - |
Long-Term Debt Issued | - | - | - | 80 | 424.68 | 663.45 |
Total Debt Issued | 28.8 | 38.11 | 0.1 | 80 | 424.68 | 663.45 |
Short-Term Debt Repaid | - | -53.35 | -21 | - | - | - |
Long-Term Debt Repaid | - | -0.65 | -0.65 | -379.55 | -630.48 | -396.66 |
Total Debt Repaid | -37.44 | -54 | -21.65 | -379.55 | -630.48 | -396.66 |
Net Debt Issued (Repaid) | -8.64 | -15.89 | -21.55 | -299.55 | -205.8 | 266.79 |
Issuance of Common Stock | - | - | - | 718.3 | 1.64 | 121.68 |
Repurchase of Common Stock | -105.59 | -105.59 | -21.82 | -586.6 | - | -120.17 |
Common Dividends Paid | -0.23 | -0.58 | -1.22 | -2,786 | -195.09 | -78.26 |
Other Financing Activities | 92.16 | 27.57 | -99.98 | -24.6 | 12.8 | 15.58 |
Financing Cash Flow | -22.29 | -94.49 | -144.57 | -2,979 | -386.46 | 205.61 |
Net Cash Flow | -59.27 | -204.8 | 79.1 | -500.4 | 246.84 | 471.72 |
Free Cash Flow | -827.71 | -448.3 | -365.39 | -64.49 | 132.79 | 37.98 |
Free Cash Flow Growth | - | - | - | - | 249.58% | -77.25% |
Free Cash Flow Margin | -28.38% | -15.09% | -10.08% | -1.73% | 2.61% | 0.78% |
Free Cash Flow Per Share | -0.82 | -0.44 | -0.36 | -0.06 | 0.13 | 0.04 |
Cash Income Tax Paid | 178.99 | 183.41 | 311.27 | 208.63 | 492.35 | 401.36 |
Levered Free Cash Flow | -49.45 | 297.03 | -389.2 | 109.14 | 525.38 | -275.7 |
Unlevered Free Cash Flow | -47.97 | 299.47 | -388.44 | 117.75 | 537.65 | -262.67 |
Change in Working Capital | 681.36 | 681.36 | -307.04 | 83.9 | 432.45 | -274.69 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.